COVID-19 is a platform for, (Doctors, physicians, research scholars, students, and business, pharma professionals) to expose their research work, to Share their knowledge in COVID-19 Vaccination. It is an occasion to interact with associates across the globe focused on learning about COVID-19 Vaccines and current research and development status. World prominent speakers, the most recent therapies and the recent modernize in COVID-19 Vaccines are trademarks of this webinar. Major scientific sessions of COVID-19 Webinar are COVID-19,COVID-19 and Impact on Healthcare, Infection Control Procedures, Vaccine Research & Development, COVID-19 case reports and clinical trials , COVID-19 risk factors and prevention and this Webinar will be attracting leading researches and decision makers in their field, principal investigators, and business professionals for sharing knowledge and research globally.
Webinar on COVID-19 Vaccination will be hosted on February 18, 2021 at 09:00 AM (GMT+4). Panel of speakers will be delivering their presentations on their recent research related to COVID-19 Vaccination. The current state of knowledge, its impact on the future will be discussed in detail. Longdom invites all experts to be part of this webinar series and make it a perfect platform for knowledge sharing and networking.
Coronavirus illness 2019 (COVID-19) is an irresistible ailment brought about by serious intense respiratory disorder coronavirus 2 (SARS-CoV-2). The illness was first distinguished in December 2019 in Wuhan, the capital of China's Hubei territory, and has since spread universally, bringing about the continuous 2019–20 coronavirus pandemic. Common indications incorporate fever, hack and brevity of breath. Different manifestations may incorporate exhaustion, muscle torment, looseness of the bowels, sore throat, loss of smell and stomach torment. While most of cases bring about gentle indications, some advancement to viral pneumonia and multi-organ disappointment.
The infection is for the most part spread during close contact and by little beads created when those contaminated hack, wheeze or talk. These little beads might be delivered during breathing; however the infection isn't for the most part airborne. People may likewise get tainted by contacting a sullied surface and afterward their face. The infection can get by on surfaces for as long as 72 hours. It is generally infectious during the initial three days after beginning of side effects, anyway it might be conceivable to spread the infection before side effects show up and in later phases of the sickness. The time from presentation to beginning of side effects is by and large somewhere in the range of 2 and 14 days, with a normal of 5 days. The standard technique for conclusion is by ongoing opposite interpretation polymerase chain response (rRT-PCR) from a nasopharyngeal swab.The contamination can likewise be analyzed from a mix of side effects, hazard factors and a chest CT examine demonstrating highlights of pneumonia.
Effective implementation of measures like closing down schools, universities, workplaces, and mass get-togethers notwithstanding social separating, could diminish the quantity of cases fundamentally and hinder its encouraging two-three months sooner.
The model took a gander at adequacy with changing degrees of isolate. It can extend on essentially at low levels, for example, 20 percent isolate. The effect on development starts to set in when 50 percent or a greater amount of contaminated people are disengaged asqto forestall spread.
Infection control deals with procedures and activities which bring to prevent or reduce the risk of transmission of infectious diseases. It is mainly works in a clinical setting or working in certain laboratories are at risk of occupational exposure to blood borne pathogens including hepatitis B (Hep B), hepatitis C (Hep C) and human immune deficiency virus (HIV) as well as occupational exposure to a range of microbiological agents. Standard analysis is the work practices needed to achieve a major level of infection control and prevention. The use of common precautions aims to reduce, and to eliminate the adequate risk of transmission of infection, particularly those caused by blood borne viruses. Microorganisms are present on hands (resident flora) or acquired during healthcare activities (transient flora). In Particular hand hygiene is to reduce the number of microorganisms on your hands, particularly transient flora which may present the greater risk for infection transmission.
Vaccine Development is an activity that focuses on a variety of technological initiatives and applied research, which enhance and promote improved systems and practices for vaccine safety. In the past year, the unprecedented Ebola disease outbreak galvanized research and industry response and as we continue to search for solutions, we must review the lessons learned in order to overcome the current challenges. Vaccines development is a long, complex process, often lasting 10-15 years and involving a combination of public and private involvement. The current system for developing, testing, and regulating vaccines developed during the 20th century as the groups involved standardized their procedures and regulations.
COVID-19 studies listed on the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). Information in the WHO ICTRP comes from clinical trial databases maintained by other countries or regions of the world. COVID-19 studies listed on ClinicalTrials.gov are not included in the list below, but can be found using our search for COVID-19.
COVID-19 is a new disease. Currently there are limited data and information about the impact of underlying medical conditions and whether they increase the risk for severe illness from COVID-19. Based on what we know at this time, people with the following conditions might be at an increased risk for severe illness from COVID-19.
Prevention:
Although there is no vaccine available to prevent COVID-19, you can take steps to reduce your risk of infection. WHO and CDC recommend following these precautions for avoiding COVID-19:
Avoid large events and mass gatherings.
Avoid close contact (within about 6 feet, or 2 meters) with anyone who is sick or has symptoms.
Stay home as much as possible and keep distance between yourself and others (within about 6 feet, or 2 meters), especially if you have a higher risk of serious illness. Keep in mind some people may have COVID-19 and spread it to others, even if they don't have symptoms or don't know they have COVID-19.
Wash your hands often with soap and water for at least 20 seconds, or use an alcohol-based hand sanitizer that contains at least 60% alcohol.
Cover your mouth and nose with your elbow or a tissue when you cough or sneeze. Throw away the used tissue. Wash your hands right away.
Avoid touching your eyes, nose and mouth.
Avoid sharing dishes, glasses, towels, bedding and other household items if you're sick.
Clean and disinfect high-touch surfaces, such as doorknobs, light switches, electronics and counters, daily.
Stay home from work, school and public areas if you're sick, unless you're going to get medical care. Avoid public transportation, taxis and ride-sharing if you're sick.
Our Brilliant Speakers
LONGDOM conferences speaker bureau map future challenges through ideation sessions by designing and validating new ideas with end users by placing right speakers in front of right audience at the right time.
French Medical professional specialized in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA vaccinology and years of active clinical practice and trained in Global health and diplomacy in Geneva (IHEAD).
Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe.
Hon. H.E. Sir. Dr. Raphael Louis, (Global Healthcare Reform Expert), is the Founder, Chairman, President & Chief Executive Officer (CEO) of The Federal Association for the Advancement of Visible Minorities (FAAVM), whereas a NFP Corporation including activities such as the FAAVM Socio Economic Development Council (SEDC), which plays a vital portion in the overall mission realization of the organization. He is also Founder/Leader of the National Coalition Party of Canada (NCPC) and believes that most Canadians who are in the slightest degree politically active are inclined to hold one of the two chief political positions common in this country, what we call conservatism or liberalism, thus politically, Canadians are highly divided. Raphael political vision when it comes to issues of finance, immigration, public health, national security, diplomacy, human rights, international trade, foreign direct investment (FDI) and environmental protection, is that government must represent Canadian interests first.
Dr. Kamal Gulati is a Ph.D. and Data Analytics Expert with 18+ years of experience in teaching and research in Computer Science and Information Technology, working as Associate Professor at Amity University, Noida India. He has also worked as Visiting Professor & Research Scholar (Under Faculty Exchange Program) CSIT Department at Stratford University, USA for two-quarters in 2016. Dr. Gulati has also worked at Bahrain University in Kingdom of Bahrain Sr. I.T. Faculty (Computer Science Department) for 2 years.
He is having experience of working with both private and public institutions with universities as the professor and self-instruction material writer for Information Technology courses. He has many research papers published in National and International Journals and conference proceedings. Dr. Gulati is also associate as Visiting / Guest (Adjunct) Faculty / Freelancer Trainer / Online Trainer / External Examiner / Question Paper Settings and Answer Paper Evaluator with various Institutes / Universities / Corporate Companies: Stratford University (Delhi & USA), IMT – Ghaziabad, FMS University of Delhi, Delhi Technological University (Formerly Delhi College of Engineering), ICFAI, KKMII, AIMA, Asian Business School, CDAC, Asia Pacific Institute of Management, IIHT, SMU, IIFP, Centre for Policy Research, Career Power, AON Hewitt, Honda-Seil, Ericsson, Vodafone, Reliance, Amity University Haryana, Mumbai, Gwalior and Jaipur, India.
Onyeka Chukwudozie is a young researcher in the field of bioinformatics, computational biology, and immunology. He obtained a first-class degree in Cell Biology and Genetics, before his huge diversion into computational modeling of biomolecules for disease studies. He has published in several international reputable journals and won awards and fellowships. Given his expertise, he has vast experience in viral studies, where he has adequately studied the genomics, transcriptomics, and proteomics characterizations of viruses such as Ebola, Lassa, and the current coronavirus. At the age of 23, he had his first sole author publication, where he adopted and applied sophisticated computational pipelines in deciphering the Ebola virus host-pathogen relationships. He has won several international awards and travel fellowships to present his prestigious research works.
Dr. Arun Srivastava is an Assistant Professor of Environmental Sciences by profession and works in India’s premiere university, JNU at New Delhi. He holds a Ph.D. degree in the field of Air Pollution from JNU and Master’s in Applied Geology from Allahabad University. Dr. Srivastava has around 20 years research experience in the different aspects of air pollution such as Indoor Air Pollution, Source Apportionment, Physical and Chemical characterisation of Aerosols, Bioaerosols and Health implications due to Air Pollution. He has also been involved in investigations of impact of air pollution on various important human organs.
Works internationally for several medical and biotech companies as scientific advisory board member and is also an active reserve-officer of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces he is CBRNe specialist with focus on (micro)biological and chemical threats and medical- and environmental functional specialist within the 1st CMI (Civil Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France he has manag from 2014 to 2019 an EU CBRN CoE public health project in West Africa. He is visiting professor at the University of Rome Tor Vergata giving lectures for the CBRN Master study.
In his civilian position he is at this moment developing with MT-Derm in Berlin (Germany) a novel interdermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy.
He has finished both his studies in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-haematology, infectious diseases, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often generated from unexpected combinations of technologies.
Open to new professional challenges and opportunities, he has an organizational development expert, with extensive experience in training development and facilitation. Specialist on Strategic and operational planning, with special emphasis on Theory of change and outcomes mapping planning, management and M&E based. I have expertise in leadership development, good governance and management skills. he have provided consultancy services to a variety of non-profit and private organization and governments. Experienced in assessment, appraisals and evaluations, management of Humanitarian aid operations in complex context. Particularly interested in organizational change processes at non profit and private sector.
Rutger Anton Middelburg is an assistant professor in epidemiology, a lecturer in research methodology and the regional coordinator for the BCG-PRIME trial; an RCT, investigating BCG-vaccination and its potential protective effect against COVID-19 in frail elderly. His main interests are under-researched groups, like children and elderly, and personalized medicine. Since obtaining his PhD, Rutger has spent 8 years in clinical transfusion research and methodological development. After a short spell working in research ethics, the COVID-19 crises brought Rutger back to clinical epidemiology. He is currently leading several research projects on the topic of SARS-CoV-2 and COVID-19.
Yan Leyfman has contributed to the development of several anti-cancer therapies that have recently entered clinical trials and his successes have been recognized by such prestigious organizations as the Barry M. Goldwater Research Foundation, Sigma Xi, New York Times, USA Today, National Society of Collegiate Scholars, and Harvard Medical School. He has been recognized as one of the top medical student researchers in oncology nationally by the American Society of Hematology and American Society of Clinical Oncology and locally by the Pennsylvania Society of Oncology & Hematology and the American College of Physicians. During the COVID-19 pandemic, he was recruited to join the Global COVID-19 Taskforce to serve as a Special Advisor for Immunology, Oncology and Cellular Therapeutics and was made Director of the Immunology Group, which produced a cohesive mechanism of action for SARS-CoV-2, a new prognostic assay to predict patient outcomes, and the first synergistic paradigm between the flu and SARS-CoV-2, termed "COVI-Flu" along with therapeutic interventions for both. Within days of publication ahead of print as the upcoming cover article in the journal, Shock, this manuscript received over 32 million views and was amongst the top five COVID-19 articles worldwide according to QxMD.
Dr. Vibhor Dudhraj is a dentist by profession and worked with one of the best private dental chain in Clove Dental, gurugram. He holds a BDS in bachelor and currently pursuing a Master of Public Health degree in Oral Epidemiology and Diseases Control at the Department of Public Health, School of Allied Health Sciences, Delhi Pharmaceutical Sciences & Research University (DPSRU), Govt. of N.C.T Delhi, New Delhi-110017. He has also been involved in outbreak investigations of infectious diseases at National Center for Disease Control (N.C.D.C), Govt. of India, New Delhi in India. He grew up in one of the remote villages of India and is passionate about controlling infectious diseases.
Prof. Dr Kazi Abdul Mannan is an Adjunct Professor of Faculty of Business Studies in Bangladesh and is currently the Director of the Migration Research and Development Society of Bangladesh (MRDSB) and Center for Academic & Professional Career Development and Research (CAPCDR). He obtained the B.Com, BA, LLB and the M.Com (Marketing) from the University of Dhaka and Doctor of Business Administration (DBA) from the Southern Cross University, Australia. In 1995, he joined the Institute of Business Studies, Moscow, as a Lecturer. Since 2005, he has been with the same Institute, where he was an Assistant Professor, and became an Associate Professor in 2000, and moved to University Uttara as a Professor. His research interests include migration, diaspora, remittance, business and public health. He has published books and has almost one hundred conference papers, articles in National and International Journals. His research interests include, Migrations, and Remittances.
What Client's Say
We let our ground-breaking work and our amazing clients speak for us…… LONGDOM conferences
Pharmaceutical biotechnologist with a PhD in neuroscience, today I work in scientific communication as a medical writer. LONGDOM Conferences is giving me the opportunity of being in contact with amazing researchers and being part of high-level scientific events.
I would like to thank you very much that you gave me a chance to participate in such great conference since all thing organized very well and I have a good new relation with new scientists from different countries. My university proud about my participation and especially it is as speaker. Thanks again.
University graduates all arrive with us buzzing from what they've done and wanting to see if the ideas they had and the approaches they took on can translate. LONGDOM conferences experience a close knit of networking and career guidance that's so valuable to us
LONGDOM conferences are a great place to make new contacts, source new products and do some research. I’ve brought my team with me and we all get something from it. You can achieve a lot in three days here.